ProJenX
1 known investors
ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company was created through a collaboration between nonprofit Project ALS, Medical Excellence Capital, and researchers at Columbia University to develop and commercialize therapeutic candidates including prosetin.
BiotechDeep TechMedical Devices
Founders & leadership
JE
Jenifer Estess
EL
Emily LowryDirector of Internal Operations at the Project ALS Therapeutics Core at Columbia
BR
Brent R. StockwellChair of the Department of Biological Science, Professor at Columbia University
HW
Hynek WichterleJerry and Emily Spiegel Professor at Columbia University
AZ
Arie ZaskFacility Manager for the Columbia University Chemical Probe Synthesis Facility
Investors · 1
In the news
- ProJenX Announces Receipt of $1M Hoffman ALS Clinical Trial Award from the ALS Association - ProjenX WordPress Siteprojenx.com · 2024
- ProJenX Holds Initial Closing of $15M Series A Financingfinsmes.com · 2023
- ProJenX Raises $15 Million to Advance Brain-Penetrant Therapies - Global Genesglobalgenes.org · 2023
- ProJenX - 2026 Company Profile, Funding & Competitors - Tracxntracxn.com · 2022